The mission is to save and ameliorate lives around the world through the discovery, development and production of innovative products and services within the realm of biotechnology.
INDUS Gene differentiates itself by the unique vision developed by its founder, Dr.C. Channa Reddy, distinguished Professor at Pennsylvania State University. The broad and ambitious scope of the vision not only includes the construction of the world's premier cGMP contract manufacturing operation, but also the inclusion of the establishment of a facility that is entirely green, which is based on solar power, and that will be known to have an international reputation of excellence regarding the biopharmaceutical industry. Indus Gene considers one of its primary goals to become a leader in the production of human and animal health products.
The global pharmaceutical contract manufacturing market was valued at USD 92.314 billion in 2017. This market is expected to reach USD 146.41 billion by 2023, at a CAGR of 8.08% during the forecast period (2018 – 2023)
Therefore, Indus Gene’s marketing opportunities for contract manufacturing of biopharmaceuticals include the largest pharmaceutical companies like Pfizer, GlaxoSmithKline, Novartis, Johnson and Johnson, etc. in the US. Indus Gene expects our South India plant to contribute significantly to the overall biopharmaceutical business and allow it to expand eventually its customer base around the world.